Grifols (GRFS) has acquired the remaining 56 percent share capital of U.S. biopharmaceutical company GigaGen for $80 million, the company announced this week in a release.
GigaGen is a U.S. biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines. GigaGen’s research focuses on discovering new biological treatments based on antibodies derived from millions of immune system cells obtained from donors.
“We are further strengthening our innovation strategy by investing in solid projects, such as Alkahest and now GigaGen, with the aim of helping patients live longer and better lives,” said Víctor Grífols Deu, co-CEO of Grifols. “Projects like these support our long-term vision and have high potential to bolster our corporate growth and business fundamentals.”
GigaGen brings a diversified pipeline of recombinant polyclonal antibodies, including GIGA-2050, a recombinant hyperimmune immunoglobulin for the treatment of COVID-19, which is expected to be evaluated in a Phase 1 trial in the U.S. in spring 2021 after the recent approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The trial, which will be the first-in-human study evaluating recombinant hyperimmune immunoglobulins, will assess the safety and tolerability of a single dose of GIGA-2050 in up to 18 hospitalized patients with confirmed COVID-19.
GIGA-2050 comprises more than 12,000 antibodies, encompassing a diverse set of anti-coronavirus antibodies captured from the convalescent blood of 16 exceptional responders to COVID-19. GIGA-2050 has strong binding activity against natural SARS CoV-2 variants, including the variants that recently emerged in several regions globally.
Source: Read Full Article